Detalles de la búsqueda
1.
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.
Arterioscler Thromb Vasc Biol
; 42(12): 1447-1457, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36325897
2.
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Circulation
; 140(19): 1578-1589, 2019 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31475572
3.
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
Cardiovasc Drugs Ther
; 34(4): 515-523, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32363493
4.
Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Cardiovasc Drugs Ther
; 32(2): 181, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29713852
5.
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Cardiovasc Drugs Ther
; 32(2): 175-180, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29627892
6.
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.
Eur Heart J
; 38(20): 1584-1593, 2017 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28329114
7.
The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.
Cardiovasc Drugs Ther
; 31(2): 179-186, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28421332
8.
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Lipids Health Dis
; 16(1): 121, 2017 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623954
9.
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.
Eur Heart J
; 37(39): 2981-2989, 2016 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27460890
10.
Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statinsã- ODYSSEY JAPAN Randomized Controlled Trial.
Circ J
; 80(9): 1980-7, 2016 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27452202
11.
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Cardiovasc Drugs Ther
; 30(5): 473-483, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27618825
12.
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
Eur Heart J
; 36(43): 2996-3003, 2015 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26330422
13.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Cardiovasc Drugs Ther
; 28(3): 281-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24842558
14.
CORRIGENDUM: Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statinsã- ODYSSEY JAPAN Randomized Controlled Trial.
Circ J
; 80(11): 2414, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27784878
15.
Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study.
Atherosclerosis
; 331: 20-27, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34303265
16.
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Eur J Prev Cardiol
; 28(1): 33-43, 2021 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755145
17.
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
J Clin Lipidol
; 14(3): 322-330.e5, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32331936
18.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study.
Am J Cardiovasc Drugs
; 20(5): 489-503, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32080823
19.
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.
J Clin Lipidol
; 14(5): 707-719, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928709
20.
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
J Clin Lipidol
; 14(1): 88-97.e2, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32192644